Colivelin
Also known as: Colivelin
Colivelin is a synthetic hybrid neuroprotective peptide that fuses activity-dependent neurotrophic factor (ADNF) with a potent Humanin derivative, studied for protecting neurons against amyloid-beta and other neurotoxic insults.
Last updated
Mechanism of Action
Colivelin is a fusion of the ADNF-derived peptide and a stabilized Humanin analog (AGA-(C8R)-HNG17), combining two neuroprotective modules into one molecule. It activates pro-survival signaling, notably the STAT3 pathway, and engages Humanin-associated receptor systems to suppress neuronal apoptosis induced by amyloid-beta, mutant familial Alzheimer genes, and prion fragments. By upregulating anti-apoptotic signaling at femtomolar to picomolar concentrations, it protects cholinergic and other neurons and has shown memory-preserving effects in rodent models.
- Half-life
- Not well characterized in humans; presumed short
- Administration Routes
- subcutaneous, intranasal
- Research Status
- Preclinical
Reported Benefits
- Potent neuroprotection against amyloid-beta toxicity in models
- Activates STAT3 pro-survival signaling
- Effective at very low (femtomolar-picomolar) concentrations
- Preserved memory performance in rodent studies
- Investigated for Alzheimer and neurodegenerative research
Potential Side Effects
- Human safety profile not established
- Possible injection-site irritation
- Unknown long-term effects on cell signaling
- Potential immunogenicity
Common Dosing
No validated human dosing exists; preclinical work used microgram-range or intracerebroventricular administration in rodents. Provided for research reference only, not medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Not for human therapeutic use
- Avoid in pregnancy or breastfeeding
- Unknown interactions with neurological medications
Humanin
Humanin is a mitochondrial-derived peptide studied for its cytoprotective, neuroprotective, and metabolic effects. The HNG (Humanin-G) analog is a more potent variant frequently used in research.
P21 (P021)
P21 (P021) is a small peptidergic compound derived from the active region of ciliary neurotrophic factor, studied for promoting neurogenesis and synaptic plasticity. It is researched preclinically as a neuroprotective and cognition-enhancing agent.
Dihexa
A small-molecule angiotensin IV analog studied for potent procognitive and synaptogenic effects, reported in preclinical work to be orders of magnitude more potent than BDNF at forming synapses.
- View
Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo
2005
- View
Colivelin prolongs survival of an ALS model mouse
2006
- View
Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease
2008
- View
Colivelin Ameliorates Impairments in Cognitive Behaviors and Synaptic Plasticity in APP/PS1 Transgenic Mice
2017
- View
Colivelin ameliorates amyloid β peptide-induced impairments in spatial memory, synaptic plasticity, and calcium homeostasis in rats.
2015